Michele Columbo, MD
General Practice · Bryn Mawr, PANPI 1538151220
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Shire North American Group Inc accounts for 61.3% of it on its own, with 41 other manufacturers making up the rest. Reporting peaked in 2019 at $54,191 and has fallen 92.5% since, to $4,062 in 2025. Among general practice clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 933 payments — averaging $85.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shire North American Group Inc$49K
- Takeda Pharmaceuticals U.S.A., Inc.$6K
- GSK$5K
- AstraZeneca$3K
- Biocryst US Sales Co., LLC$2K
- Biocryst Pharmaceuticals, Inc.$2K
- plus $12K from 36 others
Across 108 payments — averaging $436.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$47K
What the payments were for
- Consulting fees$4,8986%
- Speaking & faculty fees$47,02559%
- Travel & lodging$6,9119%
- Food & beverage$20,26126%
- Education$2460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$79,342 in reported general payments places this provider in the 95th percentile of 3,208 general practice providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 13 | $678,514 |
| OrladeyoBerotralstat Hydrochloride | 13 | $561,770 |
| Dupixent PenDupilumab | 21 | $114,228 |
| Dupixent SyringeDupilumab | 27 | $98,228 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 67 | $56,844 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 90 | $14,345 |
| Spiriva RespimatTiotropium Bromide | 19 | $13,732 |
| DuleraMometasone/Formoterol | 24 | $10,369 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $9,998 |
| SymbicortBudesonide/Formoterol Fumarate | 32 | $9,515 |
| Advair HfaFluticasone Propion/Salmeterol | 23 | $8,729 |
| Pulmicort FlexhalerBudesonide | 30 | $8,485 |
| Serevent DiskusSalmeterol Xinafoate | 14 | $5,950 |
| Azelastine Hcl | 142 | $3,519 |
| Olopatadine Hcl | 20 | $2,908 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro | $5,574 | $678,51413 claims |
| Biocryst US Sales Co., LLCOrladeyo | $2,439 | $561,77013 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $4,523 | $66,84285 claims |
| AstraZenecaSymbicort, Pulmicort Flexhaler | $3,458 | $18,00062 claims |
| Boehringer IngelheimSpiriva Respimat | $619 | $13,73219 claims |
| MerckDulera | $39 | $10,36924 claims |
| Hikma Pharmaceuticals USAEpinephrine | $19 | $2,89919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,208 general practice providers in Pennsylvania.
Other general practice in Bryn Mawr
- Corey AnolikPhiladelphia$2.1M
- Richard NagelbergPlymouth Meeting$1.4M
- Alan AtlasPhiladelphia$486K
- Susan McMahonPittsburgh$364K
- Carl MedgausMonroeville$192K
- Yooson KimMorgantown$166K
- Michael WollockArdmore$113K
- Marc ManosPhiladelphia$85K
- Robert MarusYardley$77K
- Frank RomascavageBrodheadsville$76K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.